Compare Moderna, Inc. (MRNA) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| MRNA | VCSH | |
|---|---|---|
Market Cap | $78.65B | $51.90B |
Volume | 37,373,437 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $225.00 | $80.20 |
52-Week Low | $22.36 | $77.03 |
Typical Hold Time | 59 Days | 52 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.34 with a slight 0.09% daily gain. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its competitive 4.5% dividend yield and low 0.03% expense ratio, though some analysts note tight credit spreads and downgrade it to 'Hold'. The fund's short 2.7-year duration minimizes interest rate risk but carries corporate credit exposure.
The ETF offers a higher yield than treasury alternatives but faces headwinds from limited price appreciation potential amid rising rates and compressed spreads. Key risks include credit deterioration and institutional selling. Analyst sentiment is mixed, balancing yield appeal against near-term unattractive entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
